Evidence map›Paper›PMID 24395021›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals.

Helen C Fox, Peter T Morgan, Rajita Sinha

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03137082 (Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder), which is not on this map. Cited by 85 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03137082 phase1 / phase2completednot on this mapstarted 2017, after this paper: background citation

Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)

TypeinterventionalSponsorStony Brook UniversityRan2017 to 2021Enrolled32ConditionsAlcohol AbstinenceArmsGuanfacine XR 3mgs/daily, Placebo (for guanfacine)
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Helen C FoxDepartment of Psychiatry, The Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT, USA.
Peter T MorganDepartment of Psychiatry, The Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT, USA.
Rajita SinhaDepartment of Psychiatry, The Yale Stress Center, Yale University School of Medicine, New Haven, CT, USA.
Yale University · USConnecticut Mental Health Center · US

Funding

Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
Sex Differences in Stress Related RelapseP50DA016556 · NIDA · YALE UNIVERSITY · PI SINHA, RAJITA · 2002 to 2011
$10.4M
Interdisciplinary Research on Stress, Self-Control & AddictionUL1DE019586 · NIDCR · YALE UNIVERSITY · PI SINHA, RAJITA · 2008 to 2011
$5.0M
Protocols, Statistics, Collaborative Method Development and ToolsPL1DA024859 · NIDA · YALE UNIVERSITY · PI SINHA, RAJITA · 2007 to 2011
$3.6M
Chronic Alcohol, Stress Inflammatory Response and Relapse RiskR01AA020095 · NIAAA · YALE UNIVERSITY · PI FOX, HELEN CECILIA, SINHA, RAJITA · 2011 to 2015
$1.7M
Development of Guanfacine to decrease drug craving, anxiety and cocaine relapse rR01DA027130 · NIDA · YALE UNIVERSITY · PI SINHA, RAJITA · 2009 to 2011
$1.0M
Cognitive Processes for Pharmacotherapy Development and Treatment Outcome IncocaK01DA029040 · NIDA · YALE UNIVERSITY · PI FOX, HELEN CECILIA · 2010 to 2014
$772k
NCATS NIH HHS UL1 TR000142NIAAA NIH HHS R01 AA020095NIDA NIH HHS 1K01-DA029040NIDA NIH HHS K01 DA029040NIDA NIH HHS P50 DA016556NIDA NIH HHS PL1-DA024859NIDA NIH HHS R01 DA027130NIDA NIH HHS R01-DA027130NIDCR NIH HHS UL1-DE019586
6 · The paper itself

Abstract

Currently, no FDA-approved medication exists for the treatment of cocaine use disorder. Furthermore, as women become increasingly more at risk for the consequences of cocaine addiction, the need to establish better-tailored treatment medications is paramount. We examine the effects of the alpha2 adrenergic agonist, guanfacine HCl, on responses to stress and drug cue in a group of cocaine-dependent men and women who also abuse alcohol and nicotine. Forty early abstinent treatment-seeking cocaine-dependent males and females were randomly assigned to receive either daily placebo (12 M/7 F) or guanfacine (2 or 3 mg) (15 M/6 F) for 3 weeks. In week 4, they participated in a laboratory experiment and were exposed to three 10-min guided imagery conditions (stress/stress, cue/cue, and stress/cue), one per day, consecutively in a random, counterbalanced order. Craving, negative emotion, anxiety, and cardiovascular function were assessed at baseline, immediately following imagery exposure, and at various recovery time points. Guanfacine significantly attenuated cocaine craving, alcohol craving, anxiety, and negative emotion following exposure to all three imagery conditions in females, but not males. Guanfacine did, however, reduce sympathetic tone as well as stress and cue-induced nicotine craving and systolic blood pressure (SBP) in both males and females. These findings highlight sex-specific effects of guanfacine on drug craving, anxiety, and negative mood with significant effects in women and not men. The findings suggest further evaluation of guanfacine in the treatment of cocaine use disorder with a specific focus on sex differences in treatment response.

Indexed as

Adrenergic alpha-2 Receptor AgonistsAdultAffectAnxietyArousalBlood PressureCocaine-Related DisordersCuesDose-Response Relationship, DrugEmotionsFemaleGuanfacineHeart RateHumansMaleSex CharacteristicsAdrenergic alpha-2 Receptor AgonistsGuanfacine

Identifiers

PMID24395021
PMCPMC3988558
OpenAlexW2074638725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.